Recently, Neologics Bioscience announced that its research and development pipeline NB002 for the treatment of solid tumors has successfully passed the review of the US FDA and agreed to conduct phase I clinical trials (IND number: 165196).
Shanghai Medicilon Inc, as a partner of Neologics Bioscience, provided preclinical research services such as safety evaluation and pharmacokinetics for NB002, and assisted its IND application successfully obtain FDA clinical approval. Novel humanized TIM-3 antibody NB002 is expected to open up a new path for tumor immunotherapy.
NB002, independently developed by Neologics Bioscience, is a monoclonal therapeutic antibody targeting a unique epitope of TIM-3, which has a significant single-drug anti-tumor therapeutic effect. It not only significantly activates the activity of T and NK cells and enhances their anti-tumor ability, but more importantly, NB002 rebuilds the suppressed innate immunity in the tumor environment, restores the ability of DC cells to respond, improves the antigen presentation function of myeloid cells, and holistically relieves the inhibitory effect of TIM-3 from natural immunity to acquired immunity, effectively enhancing tumor immune killing ability. The company is committed to the innovation of Best in Class and First in Class biological immunotherapy, integrating a powerful computer data mining, analysis and phenotypic target verification system to ensure the sustainable development of the pipeline.
About Neologics Bioscience
Founded in 2018, Neologics Bioscience is an innovative biopharmaceutical company, focusing on the preclinical stage of immunomodulatory biologics, and the disease areas include cancer, autoimmunity and inflammation. The company has established Tier-A platform for discovery and functional verification of immune regulatory targets, which can screen and verify multiple new cancer immune targets. At present, one project has obtained FDA clinical approval, and 5 candidate drugs are in the early discovery stage. The company has the strong support of well-known professional VCs such as Oriza Holdings, Co-Win Ventures, Yonghua Capital, and Elikon Venture. It has obtained a pre-A round of financing of more than RMB 100 million, and has established a research and development center in San Diego, USA.
About Medicilon
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. By the end of 2022, Medicilon has provided new drug R&D services to more than 1,840 clients around the world, and participated in the R&D of 330 new drug projects that have been approved for clinical trials. Medicilon is proud to contribute to human health in the globe.
Share：
Relevant News
marketing@medicilon.com
